Antiplatelet Therapy in Chronic Urticaria

C

Chulalongkorn University

Status and phase

Active, not recruiting
Phase 2

Conditions

Chronic Urticaria

Treatments

Drug: Desloratadine
Drug: Desloratadine plus cilostazol and dipyridamole

Study type

Interventional

Funder types

Other

Identifiers

NCT06268470
Chula-ARC 001/18

Details and patient eligibility

About

This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria

Full description

This study is a randomized control trial comparing the effectiveness of the combination of antiplatelets and antihistamine and antihistamine alone for the treatment of chronic spontaneous urticaria

Enrollment

12 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Chronic spontaneous urticaria

D-dimer levels over 500 ng/ml

Not respond to a conventional dose of antihistamine

Exclusion criteria

Are taking aspirin

Have bleeding tendency

Have concurrent severe medical illnesses

-

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

12 participants in 2 patient groups

Desloratadine
Active Comparator group
Description:
Oral desloratadine 20 mg/day (antihistamine) for 4 weeks
Treatment:
Drug: Desloratadine
Desloratadine plus cilostazol and dipyridamole
Experimental group
Description:
Oral desloratadine 20 mg/day (antihistamine) in conjunction with cilostazol 150 mg/day and dipyridamole 50 mg/day (antiplatelets) for 4 weeks
Treatment:
Drug: Desloratadine plus cilostazol and dipyridamole
Drug: Desloratadine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems